Key result
Indigenous anti-poison product use is linked to ~12.4-fold higher 3-year mortality in heart failure.
Why the study?
Heart failure is an important cause of morbidity and mortality, yet prospective long-term outcome data from eastern Democratic Republic of Congo are limited.
Cohort (n=235)
No
Answers are grounded in this paper and cite their sources.
In a 3-year prospective cohort of heart failure patients in eastern Democratic Republic of Congo, overall recorded mortality was 9.8%, with traditional indigenous anti-poison product use, alcohol consumption, NYHA class III-IV, renal failure, and older age identified as exploratory predictors of worse survival.
Heart failure is an important cause of morbidity and mortality, yet prospective long-term outcome data from eastern Democratic Republic of Congo are limited. We assessed all-cause mortality and explored factors associated with survival among adults with heart failure receiving care in Butembo. We conducted a prospective cohort study of 235 adults with echocardiographically confirmed heart failure at the University Clinics of the Graben, Butembo, Democratic Republic of Congo. Participants were recruited between January and February 2022 and followed for up to 36 months. The primary outcome was all-cause mortality, as cause-specific adjudication was not feasible. Death ascertainment used hospital records, family contact, and community tracing. Kaplan–Meier methods and Cox proportional hazards regression were used. Because only 23 deaths were recorded, multivariable analyses were considered exploratory. Twenty-three deaths were recorded among 235 participants (crude proportion, 9.8%). The reported mean survival time was 30.2 months (95% CI 29.0–31.0), but this estimate and the subgroup survival curves require re-analysis against the patient-level time-to-event data before they can be interpreted. The current report does not provide median follow-up, person-time, loss-to-follow-up counts, or the number at risk over time. In an exploratory Cox model, reported associations included indigenous anti-poison product use (HR 12.4, 95% CI 3.94–39.05), alcohol use (HR 2.84, 95% CI 1.50–5.37), NYHA III–IV class (HR 1.95, 95% CI 1.40–2.71), renal dysfunction (HR 1.63, 95% CI 1.01–2.63), and age (HR 1.36, 95% CI 1.12–1.65); these estimates require verification after the survival dataset and model specification are checked. This cohort provides locally relevant prospective information on heart failure outcomes in eastern Democratic Republic of Congo. The low recorded mortality and reported associations should be interpreted cautiously until follow-up completeness, event coding, and Kaplan–Meier and Cox analyses have been verified. Larger studies with more complete mortality ascertainment and detailed treatment data are needed.
No takes yet. Share an insight, caveat, or question.
Mwalitsa et al. (2026) conducted a cohort in Heart failure (n=235). Indigenous anti-poison product use vs. No indigenous anti-poison product use was evaluated on All-cause mortality (HR 12.4, 95% CI 3.94-39.05, p=<0.001). Indigenous anti-poison product use was strongly associated with increased 3-year all-cause mortality among 235 heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: